Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PSMA expression on neovasculature of solid tumors.
Van de Wiele C, Sathekge M, de Spiegeleer B, De Jonghe PJ, Debruyne PR, Borms M, Beels L, Maes A. Van de Wiele C, et al. Among authors: borms m. Histol Histopathol. 2020 Sep;35(9):919-927. doi: 10.14670/HH-18-215. Epub 2020 Apr 13. Histol Histopathol. 2020. PMID: 32282924 Review.
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Neven P, Paridaens R, Pelgrims G, Martens M, Bols A, Goeminne JC, Vindevoghel A, Demol J, Stragier B, De Greve J, Fontaine C, Van Den Weyngaert D, Becquart D, Borms M, Cocquyt V, Van Den Broecke R, Selleslags J, Awada A, Dirix L, Van Dam P, Azerad MA, Vandenhoven G, Christiaens MR, Vergote I. Neven P, et al. Among authors: borms m. Breast Cancer Res Treat. 2008 May;109(1):59-65. doi: 10.1007/s10549-007-9628-2. Epub 2007 Jun 26. Breast Cancer Res Treat. 2008. PMID: 17592772 Free article. Clinical Trial.
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ. Cocquyt V, et al. Among authors: borms m. Eur J Cancer. 2001 May;37(7):835-42. doi: 10.1016/s0959-8049(00)00416-0. Eur J Cancer. 2001. PMID: 11313170 Clinical Trial.
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F. Giuliani R, et al. Among authors: borms m. Eur J Cancer. 2007 Mar;43(4):725-35. doi: 10.1016/j.ejca.2006.11.019. Epub 2007 Jan 23. Eur J Cancer. 2007. PMID: 17251007
Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing comprehensive geriatric assessment.
Lycke M, Ketelaars L, Boterberg T, Pottel L, Pottel H, Vergauwe P, Goethals L, Van Eygen K, Werbrouck P, Debruyne D, Derijcke S, Borms M, Ghekiere V, Wildiers H, Debruyne PR. Lycke M, et al. Among authors: borms m. Psychooncology. 2014 Oct;23(10):1172-7. doi: 10.1002/pon.3540. Epub 2014 Apr 11. Psychooncology. 2014. PMID: 24729471
A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON).
Tack L, Lefebvre T, Lycke M, Langenaeken C, Fontaine C, Borms M, Hanssens M, Knops C, Meryck K, Boterberg T, Pottel H, Schofield P, Debruyne PR. Tack L, et al. Among authors: borms m. EClinicalMedicine. 2021 Aug 19;39:101081. doi: 10.1016/j.eclinm.2021.101081. eCollection 2021 Sep. EClinicalMedicine. 2021. PMID: 34466793 Free PMC article.
20 results